CRVS — Corvus Pharmaceuticals Balance Sheet
0.000.00%
- $625.09m
- $559.40m
- 37
- 18
- 91
- 46
Annual balance sheet for Corvus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 44.3 | 69.5 | 42.3 | 27.1 | 52 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.086 | 0.539 | 0.633 | 0.063 | 0.216 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 45.3 | 71.3 | 43.7 | 28 | 54.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.55 | 3.64 | 2.57 | 1.39 | 1.33 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 85.5 | 109 | 68.2 | 45.6 | 68.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12.1 | 9.69 | 10.8 | 6.87 | 35.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 13.4 | 12.3 | 12.1 | 6.87 | 36.3 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 72.1 | 97.2 | 56.1 | 38.7 | 32.6 |
| Total Liabilities & Shareholders' Equity | 85.5 | 109 | 68.2 | 45.6 | 68.9 |
| Total Common Shares Outstanding |